Abstract: The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto.

Abstract: To provide a device capable of cancer diagnosis with high sensitivity and specificity, a cancer diagnosis device (1) includes: an extracellular vesicle capturing section (16 to 18) including immobilization supports on which lectins are immobilized respectively, the lectins being each capable of binding specifically to a surface sugar chain included in an extracellular vesicle derived from a cancer cell, the immobilization supports corresponding respectively to one or more kinds of the surface sugar chain; and a detecting section configured to detect a microRNA included in the extracellular vesicle.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Abstract: The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto.

Abstract: Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: Previously, it was difficult to obtain high-affinity antibodies that specifically bind to HMGB-1 but not to HMGB-2. Under this circumstance, the present inventors successfully obtained antibodies that are more reactive to HMGB-1 than to HMGB-2 by using specific peptides as an antigen. The present inventors also demonstrated that the antibodies had a HMGB-1-neutralizing activity. The present inventors administered the antibodies to amyloidosis model animals, and as a result, successfully demonstrated that the antibodies produced a significant therapeutic effect.

Abstract: An objective of the present invention is to provide effective methods for treating interstitial pulmonary diseases including interstitial pneumonia such as IPF. The present invention suggests that antibodies against HMGB-1 are effective for treating pulmonary fibrosis. Thus, the present invention provides preparations which comprise an anti-HMGB-1 antibody for treating interstitial pulmonary diseases.

Abstract: An objective of the present invention is to provide effective methods for suppressing rejection in organ transplantation, in particular, pancreatic islet transplantation which is useful in treating diabetes. The present invention demonstrated that antibodies against HMGB-1 suppressed the rejection in pancreatic islet transplantation and promoted the survival of grafted pancreatic islets. Thus, the present invention provides agents that comprise an anti-HMGB-1 antibody for suppressing rejection in organ transplantation.

Abstract: An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention has a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.

Abstract: An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention has a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.

Abstract: The present invention provides (1) a removal material for cannabinoids present in body fluids where at least one substance from amongst substances with functional groups capable of hydrogen bonding, substances with hydrophobic functional groups, substances having cationic functional groups and physiologically active substances, is immobilized on a water-insoluble carrier, and (2) a cannabinoid removal column characterized in that it incorporates an aforesaid material (1). In accordance with the present invention, cannabinoids present in, for example, the blood, can be selectively removed.

Abstract: An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention comprises a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and/or (a) hydrophobic functional group(s) is(are) immobilized.

Abstract: The present invention is directed to a drug for preventing or remedying Alzheimer's disease. The drug contains as the active ingredient 2-phenyl-1,2-benzisoselenazol-3(2H)-one (referred as compound (A)), whose effect is based on the action of reducing neuron toxicity induced by .beta.-amyloid protein.